Advertisement
Trevi Therapeutics, Inc. (TRVI)
NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
| Previous Close | 3.1200 |
| Open | 3.1400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.0433 - 3.1400 |
| 52 Week Range | 0.9700 - 4.0000 |
| Volume | |
| Avg. Volume | 269,623 |
| Market Cap | 226.487M |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3800 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.11 |
PR NewswireTrevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November.
GuruFocus.comTrevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ...
Despite increased net losses and R&D expenses, Trevi Therapeutics Inc (TRVI) advances its clinical trials with a strong cash position and strategic hires.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.